Korean Divisional Patent Applications: Filing Periods and Scope
A Korean divisional application separates subject matter from a pending parent application into a new application. A valid divisional is treated as filed on the parent’s filing date for subject matter disclosed in the original specification or drawings. It is prosecuted, granted, and maintained as a separate case.

Korean law does not provide an unrestricted continuation procedure. A divisional must be filed within a statutory period, and it cannot add technical matter absent from the original disclosure.
Statutory filing periods
Article 52 of the Korean Patent Act permits a divisional during the following periods:
- a period in which amendment of the parent application is permitted, including the designated response period following a notice of grounds for rejection;
- within three months from service of a final rejection, subject to any applicable extension of the period for requesting reexamination or filing an appeal; and
- within three months from service of a decision to grant or a qualifying reversal decision, but no later than the date of registration.
The exact last day depends on the notice, service date, procedural status, and any valid extension. The filing period should be calculated from the official record for the parent application.
Filing date, priority, and disclosure support
A valid divisional receives the parent’s filing date and applicable priority benefit for supported subject matter. Priority data and supporting documents should nevertheless be reviewed when the divisional is prepared.
The divisional cannot introduce an improvement developed after the parent filing. Later experimental evidence may support an argument in some circumstances, but it cannot replace an enabling disclosure that was absent on the filing date. A later improvement generally requires a new application.
Examination request
The ordinary examination-request deadline is three years from the effective filing date. If that period has expired when the divisional is filed, Article 59 of the Patent Act permits an examination request within 30 days from the divisional filing date. Filing and examination instructions should therefore be prepared together.
Since July 11, 2025, a divisional application may qualify for deferred examination under the applicable requirements. Deferral is a separate request and should not be assumed from the parent’s procedural status. Preferential examination likewise requires a separate eligibility review and request for the divisional.
Lack of unity
If the examiner identifies more than one invention, the applicant may retain one invention group in the parent and file the nonelected subject matter as a divisional. The divisional claims should be drafted for the relevant commercial embodiment and the support available in the original disclosure.
Separate claim categories
A single disclosure may support apparatus, method, system, composition, use, and manufacturing claims. Separate applications may simplify examination and preserve claims directed to different infringing acts or market participants.
This can be important when a product supplier and an end user perform different portions of a method or when direct and indirect infringement require different evidence.
Parent allowance and broader divisional claims
The parent may proceed to grant with commercially acceptable narrower claims while a divisional pursues broader or differently focused claims. The divisional must still satisfy written-description, enablement, added-matter, novelty, and inventive-step requirements.
Statements and amendments made in the parent should be reviewed for consistency. A divisional does not automatically restore claim scope that is unsupported or otherwise unavailable under the prosecution record.
Competitor and standards analysis
If the original disclosure provides support, divisional claims may be directed to a competitor’s architecture, an industry standard, or a particular participant in the supply chain. Each proposed claim should be mapped to acts that can be observed and proved in Korea.
Pharmaceutical and platform portfolios
Pharmaceutical, biotechnology, materials, and software-platform applications often disclose several commercially distinct claim groups. Examples include a core structure, species, formulation, manufacturing process, use, and implementation. Separate divisionals may assign different examination and licensing objectives to those groups.
Separate application following an appeal decision
The Patent Act also provides a distinct separate-application procedure following an adverse decision of the Intellectual Property Trial and Appeal Board. This limited procedure preserves specified subject matter in a defined procedural posture. It is not an ordinary divisional application or a general continuation right.
Divisional decision record
The written filing decision should state:
- the passages in the original specification or drawings supporting each proposed claim;
- the Korean product, process, competitor, or transaction addressed by the claims;
- the current statutory filing period and its exact last day;
- the examination-request deadline, including any applicable 30-day period;
- potential double-patenting and consistency issues between the parent and divisional;
- the requested regular, preferential, or deferred examination schedule; and
- the expected filing, prosecution, grant, and maintenance costs.
A post-allowance divisional must be filed within the applicable three-month period and before registration. Payment of the registration fee should be coordinated with the divisional filing decision.
Official and additional sources
- Korean Patent Act, Article 52
- Ministry of Intellectual Property: July 2025 examination-procedure amendments
- Kim & Chang summary of the 2025 divisional examination change
- Asian Patent Attorneys Association summary of the July 2025 amendments
Related Korean patent guides
- Korean Divisional Applications: Procedure and Cost
- Korean Patent Office Actions: Response Deadlines and Recommended Strategies
- Request for Examination in Korea: Deadline, Fees and Strategy
- Patent Appeals and Reexamination in South Korea
Legal and editorial review: July 16, 2026. MOIP is Korea’s current IP authority; some official English pages may retain KIPO or transitional terminology.
This article provides general information and does not constitute legal advice. Korean law and Ministry practice may change, and the correct action depends on the facts and relevant dates.